Even though lockdown and curfew measures implemented everywhere in the world seem to have been more or less effective in the fight against the spread of the coronavirus, the number of people infected by COVID-19 in the rest of the world keeps on rising. So, to face this world’s health crisis, searchers and health professionals have been working hard to try and find an effective medication to erase COVID-19. If the vaccine may not be used for several months, clinical trials are currently carried out in some places of the globe to complete the anti-Covid arsenal.
Dexamethasone, Interferon alpha-2b, Molnupiravir, monoclonal antibodies, Calquence... As many treatments doctors from all around the world test on patients at different stage of the disease within clinical trials. And if you do not know where to start with all these tests and vaccine prototypes, we give you a list of treatments and vaccines currently studied to have a big picture of the current research works.
Vaccines studied in the world:
Vaccination in France: How many people are vaccinated as of Wednesday 27 October 2021
How many people have been given the first dose of Covid-19 vaccine in France? What are the regions vaccinating the most? This Wednesday 27 October 2021, here are how many people have been given the first dose, and been fully vaccinated in France since December 27, 2020. Keep reading to find out more about the number of people vaccinated per region. [Read more]
Vaccine in the world as of Thursday 28 October 2021: the percentage of people vaccinated by country?
As many countries have started to vaccinate people against coronavirus in late 2020, what is the percentage of people vaccinated in comparison with the total number of inhabitants in each country? Sortiraparis delivers a daily report on the vaccine situation in the world. Here are the latest data as of Thursday 28 October 2021. [Read more]
Covid: Pfizer vaccine less effective against the South African variant, a study finds
Pfizer covid vaccine is said to be less effective against the South African variant... This is at least what an Israeli study found on the matter, stating this strain is likely to "break through" the vaccine. The study shifts focus of the results from the previous study carried out by the American laboratory, explaining their vaccine was working for at least six months against all variants, and especially the South African strain. [Read more]
Covid: Valneva reports positive results for their phase 3 candidate vaccine
The French-Austrian laboratory Valneva has announced "positive topline results" for their Covid vaccine currently completing phase 3 of the clinical trial. [Read more]
Covid: Sanofi stops trials on their mRNA vaccine
This Tuesday September 28, Sanofi has announced they are halting clinical trials as for Covid mRNA vaccine as developed by American biotech Translate Bio, saying it is too late to reach the market. Yet, the vaccine was promising according to the study's preliminary results. [Read more]
Covid: Sputnik V vaccine “light” version approved in Russia
Russian coronavirus Sputnik V vaccine "light" version has been approved. This is what the Russian Direct Investment Fund announced this early May, 2021 saying that only one dose of Sputnik V could be enough to protect people vaccinated. The goal? Bringing a “temporary” solution to countries the most hit by the pandemic and enable to eradicate the spread of the virus quicker. [Read more]
Covid: German vaccine CureVac in turmoil?
Bad news for CureVac vaccine... This Wednesday June 16, the German laboratory announced their vaccine - developed with pharmaceutical and agrochemical group Bayer - did not deliver the expected results during the latest clinical trial phase, with 47% effectiveness. Disappointing results likely to slow down vaccine marketing. [Read more]
Covid: take a stock on Sanofi vaccine currently completing clincal trial phase 3
Sanofi France CEO Olivier Bogillot announced this July 5th on France Inter the vaccine developed by the laboratories will be available by December 2021. The vaccine is currently completing phase 3 of their trial. [Read more]
Covid: Nanocovax, the Vietnamese vaccine to start human testing
As many Covid vaccines are already being issued, Vietnam is just starting human testing his product developed by laboratory Nanogen, Nanocovax. [Read more]
Pfizer and BioNTech are making powdered vaccines to get round the refrigeration constraint
A few days ago already Pfizer and BioNTech announced their vaccines against coronavirus were over 95% effective! The only flaw is that these two products are to be stored at minus 80 degrees Celsius (-112°F), leading to logistical issues. Both laboratories are working on a powdered version to get round the problem. [Read more]
Coronavirus: Ose Immunotherapeutics vaccine delivers encouraging results
French laboratory Ose Immunotherapeutics has released encouraging results as for candidate vaccine against coronavirus, adding they will initiate the clinical phase in the first quarter of the year 2021. [Read more]
Treatments under clinical trial:
Covid: fluvoxamine, the antidepressant likely to cut down hospitalization risks, a study found
There is a potential new Covid drug! According to preliminary results from a Canadian study – carried out as part of the Together clinical trial – antidepressant fluvoxamine considerably decreases hospitalization risk for people contaminated. For some of them, this hazard was cut by almost a third, which is far from being negligeable. [Read more]
Covid: EMA to evaluate use of RoActemra (Tocilizumab)
Is Tocilizumab – a Covid therapy – still under rolling review? The European Medicines Agency announced they are testing RoActemra (Tocilizumab) on hospitalized severe Covid patients as it is an anti-inflammatory therapy. The drug is able to bloc interleukin-6 and prevent cytokine storms, namely a secondary inflammation of the lungs. [Read more]
Covid: take a stock on Xav-19, the French antibody-based therapy under rolling review
And what if, amid the fight against Covid, one could rely – in addition to the upcoming vaccine – on antibody-based treatments? After Bamlanivimab – the treatment developed by the Eli Lilly laboratory – or even Regeneron, this is now French Nantes-based laboratory Xenothera’s turn to present a treatment undergoing clinical trials, Xav-19. The therapy has entered the 3rd phase of clinical trial to be issued in the Fall 2021. [Read more]
Covid: WHO to review three new therapies
Are new Covid therapies to be reviewed soon? This is what the World Health Organization or WHO announced this Wednesday August 11, 2021, stating WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs namely artesunate, imatinib and infliximab. [Read more]
Coronavirus: The European Union ordered a new antibody therapy
This Wednesday July 28, the European Union announced they have secured a deal for a new experimental coronavirus therapy, Sotrovimab, developed by UK laboratory GSK. A promising monoclonal antibody therapy. [Read more]
Covid: Pfizer to develop two treatments against the virus
Two treatments against Covid are being studied, but have delivered encouraging primary results… This is what Pfizer France director David Lepoittevin announced this Friday April 9, stating that one of them was to be given orally, the other one intravenously. Two medicines that – if trials show effectiveness – could complete the existing arsenal amid the fight against coronavirus. [Read more]
Covid: take a stock on Molnupiravir, drugmaker Merck’s promising therapy against the virus
Good news amid the fight against Covid! After the FDA, drugmakers Merck & Co (Merck Sharp & Dohme, different German laboratories) and Ridgeback Bio have announced they are seeking for marketing authorization from the European Medicines Agency (EMA) for their preventive coronavirus oral therapy molnupiravir. [Read more]
Covid: take a stoke on Institut Pasteur Lille's Clofoctol therapy's clinical trial
And what if the cure against coronavirus already exists? In September 2020, searchers from Lille Institut Pasteur discovered the existence of a molecule potentially active against the virus and, in all likelihood, not leading to side effects. The therapy has been allowed by the ANSM to launch in-human clinical trial currently completing phase two. [Read more]
Covid: Eli Lilly antibody therapy said to reduce hospitalization risks, a study finds
As the race for Covid vaccines and therapies is speeding up all over the world, drugmaker Eli Lilly announced this Wednesday March 10 their antibody therapy mixing Bamlanivimab and Etsesevimab is said to reduced by 87% hospitalization and death risk in the event of severe infection. A combined therapy that received emergency use authorization back to late February from the Food & Drug Administration. [Read more]
Covid: Colchicine not working in hospitalized sick, Recovery trial found
Is Colchicine not working in Covid sick already at the hospital? This is the conclusion found by the Recovery trial in a study released this Tuesday May 18, explaining the use of this therapy "was not associated with reductions in mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death". Yet, this was a promising molecule, according to Montreal Heart Institute in a study released in March 2020 explaining Colchicine was said to be effective against Coronavirus, according to primary results from a clinical trial. [Read more]
Covid-19: Calquence, an effective treatment against cytokine shocks?
Is Claquence an effective treatment to fight against Covid-19? Pharmaceutical group AstraZeneca has announced phase 2 of their clinical trials with this potential treatment to coronavirus “did not meet the primary endpoint”. A clinical trial which point was to try and assess its effect against cytokine shocks, this violent inflammatory response from the immune system, combined with Covid-19 infection. [Read more]
Coronavirus: dexamethasone, a steroid that can reduce death by up to one third
According to a British clinical trial, a drug belonging to steroids, is said to reduce Covid-19 sick death rate by up to one third. An encouraging study as no treatment is known yet to fight against the novel coronavirus. [Read more]
Coronavirus: Kevzara underperforming as a cure to the virus, Sanofi says
This Tuesday September 1, Sanofi said they were ending their clinical trial on Kevzara as a cure against coronavirus, after noting results of this study were inconclusive. [Read more]
Coronavirus: “Positive results” for the remdesivir/diltiazem treatment the Inserm says
Searchers from the French National Institute for Health and Medical Research (Inserm) in Lyon showed that mixing two medicines, remdesivir and diltiazem, gave “positive results” for a pre-clinical phase. A new step for the discovery of an effective treatment against coronavirus. [Read more]
Coronavirus: the lopinavir/ritonavir cocktail ineffective, the Recovery trail says
Is the lopinavir/ritonavir blend to fight against coronavirus ineffective? This is what several leaders of the Recovery trial say. [Read more]
Covid: Interferon Alpha-2b, a promising therapy soon to be used in France?
Is interferon alpha-2b effective to fight against Covid? This is what a study found as it focused on the antiviral and has been released this May 15, 2020 in Frontiers in Immunology. A therapy first used against Hepatitis C, dengue, and even some cancers, specifically in South America, and enabling to dramatically improve coronavirus patient’s states of health. [Read more]
Coronavirus: does chlorpromazine, medication against bipolarity, protect against COVID-19?
Medication against bipolarity, chlorpromazine could protect yourself against coronavirus. According to the Sainte-Anne University Hospital, patients treated with chlorpromazine are less hit by COVID-19 and symptomatic cases are rare. The Institut Pasteur has just launched a study. [Read more]
Coronavirus: Anakinra, a promising treatment?
Is Anakinra an effective treatment against coronavirus? According to a French study released in The Lancet, the medicine usually prescribed for rheumatic diseases released encouraging results on severe Covid-19 forms. First results that will have to be confirmed on a greater number of patients. [Read more]
Tocilizumab, the covid treatment to dramatically reduce deaths, Recovery says
This Thursday February 11, the Oxford University released the results of Recovery clinical trial on Tocilizumab, a medication generally used in rheumatology, but here, it is used to lower the number of Covid patients in ICU. And results are particularly encouraging, echoing the study led in April 2020 by AP-HP. Here is more on the matter. [Read more]
Coronavirus: interferon beta, an effective treatment soon to be used in France?
According to the pharmaceutical company Synairgen, clinical trials about a treatment based on interferon beta – usually used against sclerosis – gave “very significative” outcomes against coronavirus. A treatment that could relieve severe cases with respiratory distress. [Read more]
Coronavirus: are plasma transfusions effective against the disease?
Is plasma transfusion an effective solution against Covid? This is one of the ongoing study topic as to cure coronavirus and it seems to deliver rather mixed results, despite an encouraging Chinese study released in April 2020. Here is more on the matter. [Read more]